Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office (USPTO) has issued notice of allowance (NOA) to Adventrx Pharmaceuticals patent application entitled 'Compositions for Delivering Highly Water Soluble Drugs.'
Subscribe to our email newsletter
The patent claims are directed to formulations of Vinorelbine Bitartrate and provide protection for the company’s lead product candidate, ANX-530 (Vinorelbine injectable emulsion), or Exelbine.
The notice of allowance is the USPTO’s official communication that the examination of the patent application has been successfully completed and that, upon timely payment of applicable fees, a patent will be issued.
Once issued, before taking into account patent term extension, the patent will provide coverage for Exelbine until July 2024.
Adventrx CEO Brian Culley said that the notice of allowance is a positive step towards the future commercialisation of Exelbine and they remain on track to submit a new drug application for Exelbine this quarter.